Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 11/20 | 0.41 |
| ▸ | CFTR | P13569 | 2/20 | 0.41 |
| ▸ | SCN7A | Q01118 | 9/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.40 |
| ▸ | CCNC | P24863 | 3/20 | 0.38 |
| ▸ | CDK8 | P49336 | 3/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.36 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24714799 | 0.86 | HPGD (0.49) | HPGDSCN9ACFTRSCN7AKCNH2 | |
| SCHEMBL18522483 | 0.81 | SCN9A (0.51) | SCN9ASCN7AKCNH2SIGMAR1SCN10A | |
| SCHEMBL8521213 | 0.73 | SCN9A (0.45) | HPGDSCN9ACFTRSCN7AKCNH2 | |
| SCHEMBL10865025 | 0.71 | SIGMAR1 (0.43) | SCN9ACFTRSCN7AKCNH2CCNC | |
| Hydrochloric Acid SCHEMBL7252859 | 0.71 | GNE (0.60) | HPGDSCN9ASCN7AKCNH2SIGMAR1 | |
| SCHEMBL11916039 | 0.70 | HPGD (0.56) | HPGDSCN9ACFTRSCN7AKCNH2 | |
| SCHEMBL7245767 | 0.69 | GNE (0.62) | SCN9ASCN7AKCNH2SIGMAR1HRH4 | |
| Hydrochloric Acid SCHEMBL31138180 | 0.68 | CD38 (0.52) | — | |
| SCHEMBL20387741 | 0.68 | CCNC (0.46) | HPGDSCN9ACFTRSCN7AKCNH2 | |
| SCHEMBL15219444 | 0.68 | PDE10A (0.48) | HPGDCFTRCCNCCDK8SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220235032-A1 | BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2022-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235032-A1 | BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | RIPK1, RIPK4, RIPK3 | HPGD 1012/4885SCN9A 4158/4885CFTR 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.